^
    Back
    Association details:
    Biomarker:PTEN mutation
    Cancer:Pancreatic Cancer
    Drug:MK-2206 (AKT inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    New
    Source:
    J Clin Oncol
    Title:

    First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors

    Excerpt:
    A patient with pancreatic adenocarcinoma (PTEN loss; KRAS G12D mutation) treated at 60 mg on alternate days experienced a decrease of approximately 60% in cancer antigen 19-9 levels and 23% shrinkage in tumor measurements.
    DOI:
    10.1200/JCO.2011.35.5263